Search

Your search keyword '"M. Pennetier"' showing total 8 results
Start Over Author "M. Pennetier"
8 results on '"M. Pennetier"'

1. Use of a new human fibrinogen concentrate (FIBRYGA®) In cardiac surgeries: first real-world experience in France based on temporary authorization

Author

S. Djabarouti, M. Pennetier, L. Gutermann, P. Clerson, C. Belmokhtar, F. Stéphan, G. Hébert, and Y. Fardini

Subjects
Anesthesiology and Pain Medicine, business.industry, Authorization, Medicine, Medical emergency, Cardiology and Cardiovascular Medicine, business, medicine.disease, Human fibrinogen
Published
2020
Full Text
View/download PDF

3. The mothif study. Costs of Clotting Factors In Haemophilia A And B: A Review From The Berhlingo Database In Seven Comprehensive Health Care Centres In France

Author

V Horvais, M Pennetier, G Chapelle, A Athouel, S Bauer, V Cogulet, C Lebert, M Clerc, I Vincent, Y Poirier, N Le Gall, V Pacaud, S Daubie, S Orhon-Ménard, M Gaumé, P Jaccard, M Haudot-Lépine, J Teil, J Huaut-Quentel, B Lassère, M Kuzzay, M Roy, A Gaudy, C Baubri, A Courtois, I Baudin Jacquemin-Aubry, N Ripoll, P Chauvet, B Pan-Petesch, L Ardillon, B Guillet, P Beurrier, F Pineau-Vincent, L Macchi, L Ferrand, M Trossaërt, and null BERHLINGO Group

Subjects
Clotting factor, business.industry, Health Policy, Health care, Haemophilia A, Public Health, Environmental and Occupational Health, Medicine, Medical emergency, business, medicine.disease
Published
2016
Full Text
View/download PDF

6. [Illustrated case study of a patient with pediatric multisystem inflammatory syndrome].

Author

Le Guen C, Leroy E, Pennetier M, Launay É, Bichali S, and Prot-Labarthe S

Subjects
Pandemics, Systemic Inflammatory Response Syndrome, Child, France, Humans, SARS-CoV-2, COVID-19 complications
Abstract

Between November 2020 and June 2021, twelve children were treated at a university hospital in western France for pediatric multisystem inflammatory syndrome (PIMS). While the clinical presentation may have been reminiscent of Kawasaki disease, PIMS, a new nosological entity, was mentioned in the media in the context of the Covid-19 pandemic. In 2023, research into this syndrome will continue in France and Europe., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)

Published
2023
Full Text
View/download PDF

7. Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres' real-life experience.

Author

Drillaud N, Babuty A, Rugeri L, Fouassier M, Lienhart A, Béné MC, Lefranc C, Ternisien C, Chamouard V, Sigaud M, Pennetier M, Trossaërt M, and Meunier S

Subjects
Adolescent, Child, Factor VIII pharmacology, France, Humans, Infant, Factor VIII therapeutic use, Hemophilia A drug therapy
Published
2020
Full Text
View/download PDF

8. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.

Author

Touzeau C, Blin N, Clavert A, Roland V, Loirat M, Tessoulin B, Le Gouill S, Planche L, Pennetier M, Mahe B, Mohty M, Malard F, Peterlin P, Dubruille V, and Moreau P

Subjects
Aged, Aged, 80 and over, Dexamethasone administration & dosage, Disease Progression, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Lenalidomide, Male, Multiple Myeloma pathology, Recurrence, Retrospective Studies, Thalidomide administration & dosage, Thalidomide analogs & derivatives, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy
Abstract

Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM). We report here a single-center series of 45 consecutive patients aged 75 years or older with relapsed MM treated with this combination. The overall response rate was 62% and the median progression-free survival was 14 months, which compares favorably to that described in the two pivotal prospective studies that formed the basis for the approval of Len/Dex in the relapse setting. Our study confirms that Len/Dex is an effective combination in very elderly patients with relapsed MM.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results